ReachMD XM Channel 157 Begins Broadcast of New Programming series "Headway on Headaches" from GlaxoSmithKline
ReachMD, the voice of the medical community on XM radio 157, today announced that it will begin broadcasting a Special Medical Industry Feature of the Week on headaches beginning Monday, Nov. 5, 2007. The eight weekly segments, developed in a partnership between GlaxoSmithKline and Elsevier, advance the understanding and treatment of one of the most common - and most commonly misunderstood - disorders: headaches. Primary headaches include migraine, tension and cluster headaches and they are prevalent and in many instances disabling. Secondary headaches are those caused by an associated disease or disorder.
Chicago, IL (PRWEB) November 6, 2007
ReachMD, the voice of the medical community on XM radio 157, today announced that it will begin broadcasting a Special Medical Industry Feature of the Week on headaches beginning Monday, Nov. 5, 2007. The eight weekly segments, developed in a partnership between GlaxoSmithKline and Elsevier, advance the understanding and treatment of one of the most common - and most commonly misunderstood - disorders: headaches.
Primary headaches include migraine, tension and cluster headaches and they are prevalent and in many instances disabling. Secondary headaches are those caused by an associated disease or disorder.
"Over the next eight weeks the station will broadcast some of the world's top thought leaders and physician experts discussing the two types of headaches that nearly everyone has had or will experience over the course of a lifetime," said Gary Epstein, CEO of ReachMD. "It is an informative and important series because national medical statistics indicate that as many as 90% of adults have had or will have tension headaches and an estimated 28 million people in the United States alone (about 12% of the population) will experience migraines."
In the United States, primary headaches often go undiagnosed or are sometimes even misdiagnosed. Migraines, for example, are frequently diagnosed as tension or sinus headaches. As a result, many migraine sufferers do not receive effective treatment. Subsequently many headaches are caused by the very medications Americans use---or misuse---to alleviate their symptoms. Migraines can vary from person to person and from attack to attack, therefore the treatment needs for each attack may also vary. Because relief can mean the difference between debilitating pain and the ability to resume activities of daily life, it is important for migraine sufferers to be accurately diagnosed and have a variety of treatment options available.
"Given how prevalent headaches are, how debilitating they can be and how varied and specific their treatments are, it's imperative for medical professionals to be up to date on the latest research and advancements so they can treat their patients safely and effectively," added Epstein.. "We are pleased to be working with GlaxoSmithKline and Elsevier to support disease understanding, diagnosis and treatment of this all too common disorder."
Some of the topics on the series will include the following medical professionals and address these and other critical topics:
Multiple Mechanisms of Migraine: K. Michael Welch, MD Understanding Medication Overuse for Headaches: Joel R. Saper, MD Treatment of Medication Overuse for Headaches: Fred Sheftell, MD Migraine or Sinus Headache? Making the Diagnosis: Mark Mehle, MD Is It Tension Headache, or Is It Migraine?: Robert G. Kaniecki, MD Understanding Menstrual Migraines: Lisa K. Mannix, MD
Listeners will be able to podcast each program online at www. ReachMD. com] or at www. headwayonheadaches. com].
"It is a great privilege to be working with two of the world's leading producers of incisive and insightful medical information," said Epstein. "ReachMD is proud to be playing a role in exploring discovery and treatment options that have the potential to help so many millions of patients who struggle with headache on a far too frequent basis."
To see the weekly schedule of the "Headway on Headaches" series and other information on programming, or, to get streaming online internet access or listen to ReachMD XM 157 go to www. reachmd. com].
About ReachMD:
ReachMD, headquartered in Highland Park, Illinois, is a leading provider of advanced healthcare information and education for medical professionals. ReachMD XM 157 remains committed to its mission of delivering highly relevant education, information and communication to medical professionals. The ReachMD XM channel is a new and innovative media vehicle that continues to deliver on this mission. The company's proprietary technology provides the most up to date healthcare information in the field through cellular phone, satellite radio and on-line programs. This technology allows healthcare professionals access to the latest information in best practices and new advances in treatment and delivers this information through convenient and accessible technologies. For more information, visit www. reachmd. com].
About GlaxoSmithKline:
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline at www. gsk. com].
About Elsevier:
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in 71 offices worldwide publish more than 2,000 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct, MD Consult, Scopus, bibliographic databases, and online reference works. Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
###
